golodirsen
Generic: GOLODIRSEN·Brand: VYONDYS 53, Vyondys 53
golodirsen: 1 clinical trial tracked.
golodirsen evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about golodirsen, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 1 study sponsors
Related indications
Study sponsors
Clinical Trial Registry Records (1)
A Long-term Observational Study Evaluating Sarepta Therapeutics, Inc.'s Exon-Skipping Therapies in Patients With Duchenne Muscular Dystrophy Under Conditions of Routine Clinical Practice
Primary endpoint: Loss of Ambulation (LOA)
Observational300 targetStarted 2019-01Completion 2033-1220 sites · United StatesSarepta Therapeutics, Inc.